GlobalStem will provide full characterization of the cells including sterility and mycoplasma detection testing, karyotyping and assaying for critical markers.
CHDI has generated various Huntington’s disease mouse embryonic stem lines as tools for researchers studying Huntington’s disease. Since each of these genetically manipulated cell lines is unique, and could potentially model different aspects of Huntington’s disease, a complete library of these lines, curated and distributed by GlobalStem, could be used to study disease mechanisms. They might also serve as novel reagents in drug screening campaigns.
Jonathan Auerbach, founder and CEO of GlobalStem, said: “The foundation has demonstrated a high level of confidence in GlobalStem with this contract award and we look forward to surpassing expectations by fulfilling the Foundation’s need for a robust and impeccable supply of cultures.”